Illumina (NASDAQ:ILMN) Releases FY 2026 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.300-5.400 for the period, compared to the consensus earnings per share estimate of 5.230. The company issued revenue guidance of $4.6 billion-$4.6 billion, compared to the consensus revenue estimate of $4.6 billion.

Illumina Trading Up 0.0%

ILMN stock traded up $0.01 during trading on Friday, hitting $205.10. The company had a trading volume of 4,099,445 shares, compared to its average volume of 1,637,936. The stock has a market cap of $31.03 billion, a PE ratio of 38.26, a PEG ratio of 3.03 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average of $176.70 and a 200-day moving average of $147.24. Illumina has a one year low of $88.00 and a one year high of $205.93.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ILMN. TD Cowen upped their price target on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday. Citigroup increased their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Guggenheim lifted their price objective on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday. Finally, Stifel Nicolaus upped their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $175.47.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last 90 days. Insiders own 2.90% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in ILMN. Empowered Funds LLC boosted its position in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Illumina during the second quarter worth $621,000. CW Advisors LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $275,000. Marshall Wace LLP increased its holdings in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC increased its position in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.